Semaglutide linked to better kidney and survival outcomes in patients with CKD and diabetes By Rebecca Jenkins Semaglutide improves kidney and survival outcomes in people with type 2 diabetes and chronic kidney disease (CKD) regardless of baseline cardiovascular disease risk, according to a secondary analysis of a randomised controlled trial
Sirtuin control of mitochondrial dysfunction, oxidative stress, and inflammation in chagas disease models
To view a copy of this license, visit About this article Cite this article Fernndez-Caso, B., Fernndez-Caballero, J.., Chueca, N
Any time there is increased stress, depression, or anxiety, the bodys need for antioxidants goes up
Disease heterogeneity necessitates rigorously designed clinical studies
2026 Phase 3 TRIUMPH Programme Update Eli Lilly's TRIUMPH Phase 3 programme is the most closely watched development in metabolic research globally as of 2026